Moderna

PacBio Announces Appointment of David Meline to Board of Directors

Retrieved on: 
Monday, October 16, 2023
Health, Master, HP, HP Inc., Amgen, London School of Economics, University, Los Angeles Philharmonic, Motion, Mechanical, Abraxis BioScience, Iowa State University, Moderna, ABB, Bachelor, Mechanical engineering, General Motors, London, Business administration, Genomics, Management, Economics

MENLO PARK, Calif., Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023. Mr. Meline was most recently the Chief Financial Officer of Moderna, Inc., a global biotechnology and pharmaceutical leader.

Key Points: 
  • MENLO PARK, Calif., Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023.
  • Mr. Meline was most recently the Chief Financial Officer of Moderna, Inc., a global biotechnology and pharmaceutical leader.
  • Mr. Meline will join the board of directors of HP Inc. effective November 1, 2023.
  • "I am thrilled to join the PacBio Board at this pivotal stage," said Mr. Meline.

TRC Amends Its Tender Offer for Moderna, Inc.

Retrieved on: 
Friday, September 29, 2023
CNRA, Moderna, Judgement, SELL, TRC, Cryptocurrency, Property management

TRC also announced that its offer will now expire at 12:01 a.m. New York City time on October 13, 2023, unless further extended.

Key Points: 
  • TRC also announced that its offer will now expire at 12:01 a.m. New York City time on October 13, 2023, unless further extended.
  • These stockholders will receive the decreased offer price of US$99.00 per share in TRC’s tender offer.
  • TRC has amended its tender offer materials to reflect the decreased offer price and other relevant changes.
  • STOCKHOLDERS CAN OBTAIN A COPY OF THE OFFER TO PURCHASE AND RELATED MATERIALS WITH RESPECT TO THE TENDER OFFER BY CONTACTING THE INFORMATION AGENT FOR THE OFFER, CNRA FINANCIAL SERVICES INC. AT (416) 861-9446.

Growing RSV Vaccine Market: Rapid Urbanization and Increasing Healthcare Expenditure Emerge as Top Market Stimulants - ResearchAndMarkets.com

Retrieved on: 
Monday, September 25, 2023
Health, Other Health, Vaccine, Urbanization, GSK, GSK plc, Prevalence, COVID-19, AstraZeneca, Research, RSV, Ageing, FDA, Merck, Epidemiology, Moderna, Pharmaceutical industry, Pfizer, Sanofi

With RSV affecting approximately 57,000 children under the age of five in the US annually, the demand for a potent vaccine is palpable.

Key Points: 
  • With RSV affecting approximately 57,000 children under the age of five in the US annually, the demand for a potent vaccine is palpable.
  • With these advancements, the RSV vaccine and antibody market is predicted to witness a CAGR of 31.65% from 2024 to 2030.
  • Growth Drivers: Factors like rising RSV prevalence, rapid urbanization, the increasing elderly population, and supportive government initiatives are fueling the market's growth.
  • They are focusing on RSV vaccine clinical trials, collaborations, innovative product launches, and expansions to meet the rising demand.

HP Inc. Names David Meline to Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Los Angeles Philharmonic, University of Chicago, PALO, HPQ, Amgen, 3M, Mechanical engineering, ABB, General Motors, Iowa State University, Mechanical, Business administration, Motion, University, HP Inc., London, Growth, NYSE, London School of Economics, Moderna, Pharmaceutical industry, Management, Economics

PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the appointment of David Meline to its Board of Directors.

Key Points: 
  • PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the appointment of David Meline to its Board of Directors.
  • “David has been instrumental in driving the growth and transformation of major global companies over the course of his four decades long career,” said Chip Bergh, Chair of HP’s Board of Directors.
  • “We are delighted to welcome David to HP’s Board of Directors,” says HP Inc. President and CEO, Enrique Lores.
  • The HP Board of Directors is one of the most diverse of any technology company in the U.S.

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Retrieved on: 
Tuesday, September 19, 2023
Vaccine, Infection, City of Hope National Medical Center, Pfizer, GeoVax, COH04S1, Public, Biotechnology, COVID-19, Messenger, CAR, City, COVID-19 vaccine, GEO, Patient, Risk, Immune system, Immunodeficiency, Death, Synthetic, Safety, Cancer, Moderna

ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of data from the ongoing Phase 2 trial of its next-generation COVID-19 vaccine (GEO-CM04S1) in the journal Vaccines. The article, authored by researchers at the City of Hope National Medical Center, can be accessed here: GEO-CM04S1 Publication.

Key Points: 
  • The article, authored by researchers at the City of Hope National Medical Center, can be accessed here: GEO-CM04S1 Publication .
  • These patients have significantly compromised immune system function and generally respond at suboptimal levels after receiving currently available COVID-19 vaccines.
  • The mRNA vaccines and monoclonal antibody therapies have been shown to be inadequate in providing protective immunity in such immunocompromised patients.
  • Vaccines that are “variant-agnostic” such as GEO-CM04S1 will increasingly be critical to reducing such risks, protecting the most vulnerable populations and improving our ability to overcome such infectious threats.”

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 12, 2023
CLL, Vaccine, Chronic lymphocytic leukemia, SARS-CoV-2, Public, Biotechnology, COVID-19, Smallpox, Head, Breast, Infection, Prostate, Messenger, Monoclonal antibody, Hematological Cancer Research Investment and Education Act, Labs, Patient, Cancer, Immunodeficiency, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NIH, Conference, Food, Pfizer, MVA, Pharmaceutical industry, Moderna

ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11. A webcast replay of Mr. Dodd’s presentation can be viewed here.

Key Points: 
  • ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11.
  • A webcast replay of Mr. Dodd’s presentation can be viewed here .
  • During his presentation, Mr. Dodd reviewed the Company’s four ongoing Phase 2 clinical trials:
    As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy).
  • As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine.

Global mRNA Cancer Vaccines Market Set to Reach $6.71 Billion by 2030 Driven by Research, Investment, and Partnerships - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Health, Oncology, Vaccine, BioNTech, Intellectual property, Investment, Biotechnology, COVID-19, Cancer, Research, Messenger, Moderna, Pharmaceutical industry, Genentech, Merck

The "Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The global mRNA cancer vaccines market is undergoing a paradigm shift, propelled by intense research, robust investment, and strategic alliances.
  • Global pharmaceutical giants and biotechnology innovators are forming strategic alliances, shaping the commercial trajectory of mRNA cancer vaccines.
  • The global reach of mRNA cancer vaccines calls for understanding regional healthcare ecosystems and collaboration with stakeholders.

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

Retrieved on: 
Wednesday, September 13, 2023
SAB, Nobel Prize, DNA, Bevacizumab, National Academy of Medicine, Administration, Biotechnology, National Academy of Sciences, Herv, Cancer, United States Air Force Scientific Advisory Board, National Medal, National Academy of Engineering, Medicine, MIT, RNA, HERV, Regenerative medicine, Blood, Professor, National academy, Anpartsselskab, Tissue engineering, Moderna, Immune system, Novo Nordisk Foundation, ARD International Music Competition, Viral, Drug development, BII, Therapy, Pharmaceutical industry, Vaccine

COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).

Key Points: 
  • COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).
  • Professor Robert S. Langer, newly appointed Chair of HERVOLUTION's Scientific Advisory Board, commented: "Oncology needs a paradigm shift.
  • Dr Peter Holst, Founder and Chief Scientific Officer of HERVOLUTION, said: "We are honoured to welcome Professor Langer as Chair of HERVOLUTION's Scientific Advisory Board.
  • Prof Langer is the co-founder of Moderna Therapeutics and Professor at the Massachusetts Institute of Technology (MIT).

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

Retrieved on: 
Wednesday, September 13, 2023
SAB, Nobel Prize, DNA, Bevacizumab, National Academy of Medicine, Administration, Biotechnology, National Academy of Sciences, Herv, Cancer, United States Air Force Scientific Advisory Board, National Medal, National Academy of Engineering, Medicine, MIT, RNA, HERV, Regenerative medicine, Blood, Professor, National academy, Anpartsselskab, Tissue engineering, Moderna, Immune system, Novo Nordisk Foundation, ARD International Music Competition, Viral, Drug development, BII, Therapy, Pharmaceutical industry, Vaccine

COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).

Key Points: 
  • COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).
  • Professor Robert S. Langer, newly appointed Chair of HERVOLUTION's Scientific Advisory Board, commented: "Oncology needs a paradigm shift.
  • Dr Peter Holst, Founder and Chief Scientific Officer of HERVOLUTION, said: "We are honoured to welcome Professor Langer as Chair of HERVOLUTION's Scientific Advisory Board.
  • Prof Langer is the co-founder of Moderna Therapeutics and Professor at the Massachusetts Institute of Technology (MIT).

FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

Retrieved on: 
Monday, September 11, 2023
EUA, Vaccine, BioNTech, Advisory Committee on Immunization Practices, Immunization, Vaccination, Omicron, Hospital, Public, Advisory Committee, COVID-19, Center for Biologics Evaluation and Research, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Messenger, Formula, Risk, Immunodeficiency, Research, FDA, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Food, Pharmaceutical industry, Moderna

Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines as described in the respective prescribing information or fact sheets.

Key Points: 
  • Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines as described in the respective prescribing information or fact sheets.
  • The updated vaccines are expected to provide good protection against COVID-19 from the currently circulating variants.
  • Manufacturers have publicly announced that the updated vaccines would be ready this fall, and the FDA anticipates that the updated vaccines will be available in the near future.
  • This suggests that the vaccines are a good match for protecting against the currently circulating COVID-19 variants.